DMSO, Tinnitus, and the Signal We Cannot Ignore: Why DART-TINN Continues

A patient recently forwarded me Dr. Russell Blaylock’s newsletter “Rethinking Dimethyl Sulfoxide.” In it he cites cell-culture and developmental-animal data suggesting low-dose DMSO can promote α-synuclein aggregation, impair astrocytes, damage mitochondria, and harm developing neurons. The concern is real and deserves a direct response—especially for those enrolled in or considering our registered pilot, DART-TINN (NCT07567274).

I am the principal investigator of that study, which is funded by the non-profit Rebuild Medicine. We are testing a dual-route, compounded DMSO regimen specifically for refractory subjective tinnitus that began or worsened after PASC or COVID-19 vaccine injury. More than 500 of our roughly 4,000 patients carry this symptom; for many it is relentless and life-altering. “Nothing we can do” is no longer an acceptable answer.

A Midwestern Doctor has spent the last two years assembling the largest accessible review of DMSO’s history, toxicology, and clinical use. He documents decades of human exposure (hundreds of thousands of patients), high-dose toxicology studies across species that found no major organ toxicity, and protective effects—radical scavenging, improved microcirculation, anti-inflammatory action, and the ability to revive stressed cells. Common effects are garlic odor and transient skin irritation. Severe reactions are rare. AMD frames the FDA’s long-standing restrictions as political and economic rather than driven by genuine safety signals. Mary Beth Pfeiffer’s recent investigative piece, “Stanley Jacob’s Remarkable Medicine Was Buried by Government. But DMSO Lives,” reaches a similar conclusion after reviewing the historical record, patient outcomes, and the work of clinicians who have brought DMSO back into practice.

Blaylock focuses on specific preclinical findings: a 2022 Scientific Reports paper showing DMSO accelerates α-synuclein oligomerization in vitro and in cells (though the oral mouse arm showed no pathology); a 2014 study in which 1 % DMSO impaired mitochondrial function and glutamate handling in cultured astrocytes; and developmental work demonstrating apoptosis in the immature mouse brain. These are legitimate signals that any responsible clinician must weigh.

The tension is largely one of model, dose, and route. Culture-medium concentrations and direct exposure of developing neurons are not the same as short-course, local adult human use.

We are not giving high-dose systemic DMSO. Participants receive two compounded formulations for 30 days:

• An otic liquid (50 % DMSO + betahistine + low-dose dexamethasone + lidocaine) instilled into the external canal every four days.

• A transdermal cream (DMSO base with N-acetylcysteine and levocarnitine) applied once daily to the periauricular skin, mastoid, and upper neck.

This dual local route concentrates the solvent’s penetration, anti-inflammatory, and vasodilatory properties at the cochlear microvascular bed—the precise territory we believe is compromised by spike-related fibrin microclots, iron dysregulation, and endothelial injury—while keeping systemic exposure low. The design modernizes a 1975 open-label series in which a similar DMSO combination produced complete or substantial, sustained resolution of tinnitus in most patients, accompanied by a rise in tympanic temperature consistent with improved local perfusion.

Primary endpoint is a ≥50 % drop in Tinnitus Handicap Inventory score at Day 30 in at least half the cohort. We collect safety data, secondary symptom clusters, and longer-term follow-up precisely so we can detect any unexpected neurological signal early.

The α-synuclein and mitochondrial findings deserve respect. They do not, however, override the accumulated human safety data at the concentrations and routes we are using, nor the historical tinnitus signal, nor the mechanistic fit with the microvascular pathology we see every day in clinic. Local delivery plus the antioxidant and mitochondrial-support adjuncts in the cream further reduce the theoretical risk Blaylock highlights.

We monitor closely. Any new or worsening neurological symptom triggers immediate review. Iron indices, fibrin markers, and inflammatory panels remain part of our broader evaluation so we can test whether auditory improvement tracks systemic microvascular recovery.

Blaylock’s caution is useful; it keeps us precise about dose, purity, route, and duration. AMD’s and Pfeiffer’s work remind us that a compound with this breadth of historical clinical activity should not be abandoned on the basis of cell-culture data alone—especially when patients are suffering a refractory, spike-linked symptom for which conventional options offer little.

If you are in the study or considering it, bring every concern. We will walk through the data, the design choices, and the monitoring plan together. The goal remains the same: generate a clear signal—positive or negative—while protecting every participant.

Tinnitus in this population is not “just ringing.” It is often a sentinel of the same iron–fibrin–microvascular injury we track elsewhere. DART-TINN is one careful attempt to meet that injury where it lives. We will follow the results wherever they lead.

Scott Marsland, FNP-C
Principal Investigator, DART-TINN